Portage Biotech Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer
The company is dedicated to advancing its proprietary drug candidates through various stages of clinical development, aiming to address unmet medical needs in oncology. By leveraging its scientific expertise and strategic partnerships, Portage is engaged in researching and developing novel immunotherapies and personalized medicine approaches that aim to improve patient outcomes and enhance the efficacy of existing cancer treatments.
A new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies— Peraso Inc. (NASDAQ: PRSO), Lexicon Pharmaceuticals (NASDAQ: LXRX), Portage Biotech (NASDAQ: PRTG), and TransCode Therapeutics (NASDAQ: RNAZ) —each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Portage Biotech stock is trading higher after the company announced it signed a letter of intent with Immunova for the potential sale of its subsidiary.
Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today.
